HedgeChatter

  • Home /
  • Tag Archives

AMAG

Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients

[GlobeNewswire] – WALTHAM, Mass. — AMAG Pharmaceuticals, Inc. today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.285 moreView todays social media effects on AMAGView the latest stocks trending across Twitter. Click to view dashboardSee who AMAG is hiring next, click here to view […]

February 18, 2014 Bystocknews , Comments Off on Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients read more

AMAG PHARMACEUTICALS INC. Financials

moreView todays social media effects on AMAGView the latest stocks trending across Twitter. Click to view dashboardSee who AMAG is hiring next, click here to view […]

February 13, 2014 Bystocknews , Comments Off on AMAG PHARMACEUTICALS INC. Financials read more

AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019

[GlobeNewswire] – WALTHAM, Mass. — AMAG Pharmaceuticals, Inc. today announced the pricing of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019 (the notes) in an underwritten … moreView todays social media effects on AMAGView the latest stocks trending across Twitter. Click to view dashboardSee who AMAG is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019 read more